BioAlliance Pharma reacquires the rights to Loramyc in Europe
BioAlliance Pharma has initiated legal proceedings in Paris against SpeBio for violation of the latter’s contractual obligations and in order to obtain appropriate compensation for losses suffered as a result of delays in commercialization and sale of Loramyc®.
BioAlliance Pharma is confident in ensuring the continued Europe-wide commercialization of Loramyc® directly in selected countries and through specialist oncology partners in other countries.
Most read news
Topics
Organizations
Other news from the department politics & laws
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.